WO2006014968A3 - Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders - Google Patents
Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders Download PDFInfo
- Publication number
- WO2006014968A3 WO2006014968A3 PCT/US2005/026510 US2005026510W WO2006014968A3 WO 2006014968 A3 WO2006014968 A3 WO 2006014968A3 US 2005026510 W US2005026510 W US 2005026510W WO 2006014968 A3 WO2006014968 A3 WO 2006014968A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compounds
- methods
- nitroxydes
- nitroxides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed are compounds having the structure wherein Z is -OH or O ; and A is wherein X and Y are independently NR1or O, where R1 is H or C1-C4 alkyl ; and R2 is H, C1-C4 alkyl or t-butoxycarbonyl, wherein W is C3-C4 alkynyl ; and R1 is H or C1-C4 alkyl, or wherein R1 is H, C1-C4 alkyl, or C3-C4 alkynyl ; and R3 is H, OH, O (C1-C4 alkyl) , or a halogen, optically active enantiomers, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions containing such compounds or salts, and processes for their preparation. The subject invention also provides methods of alleviating symptoms of neurologic, autoimmune, and inflammatory disorders caused by the presence of reactive oxygen species, methods of preventing oxidation of lipids, proteins, or deoxyribonucleic acids on a cellular level, and methods of protecting human red blood cells from lysis by 02 radicals.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90098404A | 2004-07-27 | 2004-07-27 | |
| US10/900,984 | 2004-07-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006014968A2 WO2006014968A2 (en) | 2006-02-09 |
| WO2006014968A3 true WO2006014968A3 (en) | 2006-11-09 |
Family
ID=35787775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/026510 WO2006014968A2 (en) | 2004-07-27 | 2005-07-26 | Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006014968A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2696310A1 (en) * | 2007-08-14 | 2009-02-19 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services, The | Method of treating disease involving myelin and/or axonal loss |
| IT1392914B1 (en) * | 2009-01-22 | 2012-04-02 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF (R) -N-PROPARGIL-1-AMMINOINDHANE AND ITS SALTS |
| KR102076874B1 (en) * | 2012-04-03 | 2020-02-12 | 쉰들러, 윌리엄 | Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457133A (en) * | 1990-01-03 | 1995-10-10 | Teva Pharmaceutical Industries Ltd. | R-enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US6303650B1 (en) * | 1996-12-18 | 2001-10-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Aminoindan derivatives |
| US6956060B2 (en) * | 1990-01-03 | 2005-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
-
2005
- 2005-07-26 WO PCT/US2005/026510 patent/WO2006014968A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457133A (en) * | 1990-01-03 | 1995-10-10 | Teva Pharmaceutical Industries Ltd. | R-enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US6956060B2 (en) * | 1990-01-03 | 2005-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| US6303650B1 (en) * | 1996-12-18 | 2001-10-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Aminoindan derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006014968A2 (en) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107266332B (en) | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof | |
| JP6250608B2 (en) | Cyclosporine analog | |
| NO20064450L (en) | Pyrazolo [3,4-β] pyridine compound and its use as a PDE4 inhibitor | |
| NO20062101L (en) | Serine protease inhibitors, especially hcv ns3-ns4a protease | |
| NO20060706L (en) | Inhibitors of serine proteases, especially HCV NS3-NS4A protease | |
| NO20100093L (en) | Peptidomimetic protease inhibitors | |
| WO2003000695A8 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| NO20071776L (en) | Kinoxalines as B RAF inhibitors. | |
| EP2153832A3 (en) | Heterocyclic aspartyl protease inhibitors | |
| TW200612951A (en) | New pyridazin-3(2h)-one derivatives | |
| NO20055496L (en) | Pyrazoloquinazoline derivatives, methods for their preparation and their use as kinase inhibitors | |
| CA2367017A1 (en) | Inhibitors of impdh enzyme | |
| WO2005000298A3 (en) | 5-membered heterocycle-based p-38 inhibitors | |
| WO2005077969A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| UA85708C2 (en) | Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases | |
| US9561259B2 (en) | Cyclosporin analogs | |
| EP2261224A3 (en) | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | |
| MX2008013836A (en) | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| NO20064811L (en) | 4- (5-Aminomethyl-2-fluoro-phenyl) -piperidin-1-yl] - (4-bromo-3-methyl-5-propoxy-thiophen-2-yl) -methanone hydrochloride as an inhibitor of mast cell tryptase | |
| WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| UA88634C2 (en) | Quaternized quinuclidine esters | |
| WO2005097762A3 (en) | 1,3,4-oxadiazol-2-ones as ppar delta modulators | |
| WO2006055434A3 (en) | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| DK1641454T3 (en) | Pyrazolo [3,4-B] pyridin-6-ones as GSK-3 inhibitors | |
| RU2008102249A (en) | PREVENTIVE OR THERAPEUTIC AGENT FOR CORNEAL / CONJUNCTIVE DISEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |